



#### FY 2012 Results 19 September 2012

NEXT GENERATION NUTRITION



### **NEW GROWTH HORIZONS**

- Strategic vision & business description
- 2012 financial performance
- Operational review
- Clover's competitive strengths
- New growth horizons
- Outlook & priorities



#### **STRATEGIC VISION**

**Clover Corporation seeks to:** 

- Identify, develop and commercialise speciality functional and nutritional ingredients in the growing "nutraceutical" market
- Develop and commercialise leading edge proprietary and patented delivery technology including encapsulation
- Work with innovative and multinational industry partners to leverage core technical and manufacturing strengths to innovate and launch new products and expand in core markets
- While retaining a conservative financial base, deliver growth on earnings and dividends




### **BUSINESS DESCRIPTION**

- Focus on two business units:
  - Clover Corporation focuses on innovation & obtaining the optimal return from proprietary technology
  - Nu-Mega Ingredients commercialises proprietary ingredient delivery and encapsulation technology in targeted value added markets
- Work with customers to identify, design, develop, test & launch new products
- Generate sales directly and through specialist distribution partners
- Maintain strong links with technical & academic agencies including CSIRO
- Employ 33 staff, including 4 PhD's, with offices in Sydney, Melbourne, Brisbane and the UK

## OVERVIEW OF NU-MEGA PRODUCTS



Maximize the use of proprietary bioactive delivery technology



# CLOVER FY2012 RESULTS year ended 31 July 2012



AUD million	4E Reported 31 July 2012	4E Normalised* 31 July 2012	PCP 1 Aug'10 – 31 Jul '11	4E Reported# 31 July 2011
Revenue	\$38.4	\$38.4	\$32.0	\$35.6
Profit before tax	\$6.4	\$7.4	\$5.2	\$6.1
Depreciation/Amort Interest	(\$0.51) \$0.29	(\$0.51) \$0.29	(\$0.36) \$0.55	(\$0.39) \$0.59
EBITDA	\$6.7	\$7.9	\$5.1	\$5.9
EBIT	\$6.2	\$7.4	\$4.7	\$5.5
Тах	(\$1.99)	(\$1.99)	(\$1.26)	(\$1.53)
NPAT	\$4.4	\$5.6	\$4.0	\$4.6
EPS	2.65 cps	3.38 cps	2.40 cps	2.79 cps
ROE (annualised)	14.5%	18.6%	14.1%	16.4%

\* Normalised results are non-statutory measures and represent results from continuing operations. Expenses totalling \$1.22 million in respect of the joint venture, Future Food Ingredients Pty. Limited, have been excluded from the normalised results.
 # Due to change in Financial year includes 13 months from 1 July 2010 to 31 July 2011.

#### NEXT GENERATION NUTRITION

## HISTORICAL FINANCIAL PERFORMANCE



AUD million	FY2012	FP2011 (13 months)	FY2010	FY2009	FY2008	FY2007
Shares on issue	165.2 m	165.2 m	165.2 m	165.2 m	165.2 m	165.2 m
Total contributed equity	\$29.9	\$32.9	\$32.9	\$28.3	\$27.0	\$23.7
Cash total	\$9.7	\$7.4	\$12.2	\$9.2	\$10.8	\$11.0
Sales Revenue	\$38.4	\$35.6	\$34.9	\$21.1	\$21.6	\$16.5
Total Revenue	\$38.7	\$36.0	\$35.9	\$22.9	\$22.9	\$17.7
Profit before tax	\$6.4	\$6.1	\$1.6	\$4.5	\$3.0	\$1.3
Profit after tax	\$4.4	\$4.6	(\$0.97)	\$3.1	\$4.1	\$0.6
EPS (cents)	2.60	2.70	(0.59)	1.87	2.5	0.38
Dividend (cps)	1.75	1.50	1.25	1.00	1.00	

# CASH FLOW Year ended 31 July 2012



AUD million From Continuing Ops	Reported 31 July 2012
EBITDA	6.7
Working Capital Movement	3.4
Net Interest	0.3
Tax Paid	(2.4)
Cash Flow from Operations	8.0
Financing Activities	(3.8)
Сарех	(1.9)
Free Cash Flow	6.1
Net Increase in Cash Held	9.7



### BALANCE SHEET Year ended 31 July 2012

AUD million	Reported 31 July 2012	Reported 31 July 2011	Change %
Cash	9.7	7.4	+31%
Trade Receivables	9.7	10.5	-9%
Inventories	12.3	8.7	+41%
<b>Total Current Assets</b>	31.8	27.1	+17%
PPE/Intangible Assets	5.5	4.1	+34%
Total Assets	38.6	32.3	+20%
Trade Payables	(8.1)	(3.4)	+138%
<b>Total Current Liabilities</b>	(8.4)	(4.0)	+110%
Total Liabilities	(8.7)	(4.3)	+102%
Net Assets	29.9	28.0	+7%

NEXT GENERATION NUTRITION

#### FY2012 HIGHLIGHTS – STRONG UNDERLYING GROWTH



- Strong growth in organic sales revenue (20.7% normalized pcp).
- Focus on infant formula & children applications (2012: 97.4%).
- Continued expansion of sales in Oceania and Asia.
- Increase in proportion of sales from high value encapsulated products (2012: 97%).
- Reduction in costs due to productivity improvements and other efficiencies.
- 5% decrease in underlying NPAT due to costs of \$1.22 million associated with sale of FFI assets. Sales contracts have been exchanged.
- Customer evaluation of new products are underway.
- Innovation program with CSIRO Australian Growth Partnership program underway.
  Due for completion in 2014.
- Novel Food approval by Health Canada for selected encapsulated ingredients.
- Upgrade of the Altona manufacturing facility (\$1.5 million).
- Generating positive free cash flow (2012: \$6.1 million).

#### CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED PRODUCTS



- Sales revenue increased in all regions with the strongest performance in Australia/New Zealand and Asia.
- Focus has been on infant formula & children's food applications.
- The expansion of sales in value added encapsulated ingredient systems.

#### FY2012 Geographic

Australia/New Zealand	26%
Asia	64%
Europe	6%
Americas	4%


#### FY2012 Products

Oil	3%
Encapsulated Powders	97%

# MULTIPLE GROWTH DRIVERS & DELIVERY



- Maintaining a position at the forefront of technical development for bioactive delivery and encapsulation technology
  - 2 patent applications filed in FY2012
- Working with our customers to develop & provide market relevant proprietary products in a timely manner
- Focus on growing and emerging markets
- Identifying value added applications
- Investigation of specific opportunities for medical foods for preterm infants.




#### DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES



• Product portfolio includes refined tuna oil and encapsulated powders containing marine oil, algal oils, other specialty oils and important micronutrients.

• Encapsulation technologies protect important and sensitive nutritional materials and allow their use in many applications. Sales Revenue based on Diversified Bioactives in FY2012




□ Tuna oil encap. □ Other bioactive encap.

# **COMPETITIVE STRENGTHS** – A CULTURE OF COMMERCIAL INNOVATION




- Clover's core strengths;
  - Growing share in value added markets
  - Proprietary & patented technology
  - Commercial focus with high returns on R&D
  - High quality products & excellent reputation with clients
  - Dedicated and skilled staff
- Long term commercial relationships
- Expanding product portfolio supported by sound science
- Targeted external research program
- Long product life cycle supported by rigorous customer evaluation
- Excellent customer & applications support
- Specialised distribution network
- Low capital model



#### RESEARCH & DEVELOPMENT EXPENDITURE

(EXPENSED IN YEAR OF ACTIVITY)






\* FP11 represents 13 months

#### **EXAMPLE OF PRODUCT LIFE CYCLE**




#### Continual product improvement to increase sales



Time

# INNOVATION LEADS TO NEW PRODUCTS & REVENUES





# SPONSORED RESEARCH **IN 2012**



Heart <i>Rhy</i> i	hm		
The Official Journal of the Heart Rhythm Soci	ety		
Articles and Issues - Multim	edia - Article Collections - For Au	rthors - Journal Info - HRS	- Related Sites -
Search for	in All Fields	Go Atvance	ed Search
•Previous	Heart Rhyt <u>Volume 9, Issue 4</u> , Pages 4		Nexto
reduces the recu electrical cardior	Fiona Sutherland, RN. Joseph B. Noton, ME ECCleston, MBBS, NMed, John Vaukelatus	atrial fibrillation a	Ifter
Objective We examined iffong-term supp	mages References Suppleme is associated with a high risk of recurrence lementation with one epa-3 polyunsaturated faued thereafter reduces recurrence of pers	Actly acids in £sh oils commenced >1	I meath prior th
group (n = 87) or om ega-3 grou so taloi or amioclarone was pern	ized study of 178 patients with persistent A p (6 g) d dsh oi); = 91; and underwent card rited, Fish oi) was confuned fill return of pe primary endpoint defined as the recurrence	loversion 1 month later. Concurrenta ersistent AF or a maximum of 1 year.	antarrhythmic use of
	vas 56 days precardioversion aucla 1010 of e components offsh oils, were 1.8-101d auc		

- AL

Nauchinings of Aging 33 (2012) \$28.41-\$28.43 Negative results

The effects of 90-day supplementation with the Omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population

Con Stough\*\*, Luke Downey\*, Beata Silber\*, Jenny Lloyd\*, Christina Kure\*, Keith Wesnes<sup>a,b</sup>, David Camfield<sup>a</sup>

Recent IF Dented - 1 - Der Film Continent of
 applementery blocks (2007), Dentembergi
 \* Performing
 \* Performi

#### Abstract

The emaps? http sold docustreaming and (SDA) is essential for nervous system and mintil docksponent and there is arsidence to suggest that DIAA dedinations intensive with memal aging. A triple/dotad platehocustreful standardine dependences that was encodended with 1 Abathy persignation, aging 14:207 years. Cognitive and visual cost presents and plates that due 100A very determinist at banding and alar WD days of administration of other BEDBA\* (Chorer Corp., Sydney, NOW, Anstalia: 100D reg of twas is), comprising at banding and alar WD days of administration of other BEDBA\*. at busine and zero flags of advantations of other BRBM CS Career Cape, 3 policy, 30%, bandrals, 100% ray of an asso (comparing) 200 gal (BK). Sing of policy and long visuants in 1 policy (1000 gal (200 gal (20

Knowedy: Essential have acide: Decombetrazionic acid (DBIA); Gerlanico: Demonity: Nathine; Cognition; Visual Acator

#### 1. Introduction

Derivality are set of (DHA) is a long chain so-3 poly-mantened farty acid (DHA) is a long chain so-3 poly-field with a set of the set of the set of the set of the photppi composition of gluona montheness in the brain photppi composition of gluona montheness in the brain photppi composition of gluona montheness in the brain (former P-walls, 2008; finalized or 4, 2008; Fipidaminopi-cal and prospective colour research has provided strong reference to indicate that a des heights in this and enviros ac-3

<sup>4</sup> Carengonding autor at: Noisoid Institute of Complementary Medi-cian (NICM) California's Court for Nonecognition. Brain Sciences Institutes: Vieweng of Technology, PO Jan 228 Hontlers, Medineum Viewen 1027, Ameraila, Tal: +60 3 9214 8165; Int + 61 3 9214 9286.

A real address completion is one of . Imagin

0097-49809 - see front matter © 2012 Elsevier Inc. All rights reserved. doi:10.10166.eeendhologing.2011.01.019

#### is lisked to a lowered risk of cognitive decline and Alzhei-

is listed to a lowersh this of cognitive decision and Admin-net's bases (AD) (Bripchan et al., 2007; Mortis et al., 2005; Yua Gelden et al., 2007). However, chained evidence from effecting of DBA is multimating cognitive decises has not been without some sime. Is an entrume review of DBA chained table do-menda, Caranae and arlinguess (2009) concluded that there is carantly partiant evidence for DBA julying a pre-sentier on ther this corative usis is detected and anti-entiers of the theoremican later review handles more handles and the second second second second second second second section. Second secon

ANT ANT

trather multi-main customers whi is a determine, independent trades that have investigated the cognitive baselits associ-and with DHA supplementation in healthy elidenty indivi-als without criterione of determinist have also yielded mixed results; with some reporting modest cognitive improve-ments (Fortanti et al., 2005; Mixenso et al., 3009; Yaria-Mauro et al., 2010), while a large study by Yan. De Hest et

corerol group), from the start of bottle-feeding or 6-months of age until 5 years of age. Canstid intera-media thickness 1907), a noninvasive measure of subclinical afterosciences, was the primary evolpties of a cardiovascular substudy (CardioCAVS) at age 8 years. We examined the succession of fetal growth with carotid IMT in children with birth weight, <30th percentile

RESULTS: In the control group, fetal growth was inversely associated with carotid MT, but this was prevented in the onega-1 group difference between groups of 0.041 and 35% confidence interval 0.006, 0.07% per log birth weight, adjusted for gestational age and gender,  $P_{\rm ique space by}=0.0$ 

CONCIDENTS. The inverse amoritation of family anoth with a starial and

#### PEDIATRICS

tens About Consettance AAP Policy aAntrives Supplements Callectons eLetters Early Releases ContactU + Perines | Beet Article + Table of Contents . Courses and This Article Impaired Fetal Growth and Arterial Wall Following the following St. 2011 PERCENT Inst Little Percent is Thickening: A Randomized Trial of log k Canacita Reser Range By Amerit Richanst Richanst Richanst Rachanst Rachanst 211 19-0214-9708 4-0216-9708 4-0216-9802-9812-0111-0872 Omega-3 Supplementation

- Albertant Steel Fall Test (PDD)

Atida Tgos

.....

Service:

Jonal Historick to a filmed
 Alor on allow this orbits in
 Alor on allow this orbits in
 Alor on allow definition on
 pathola
 Tenda andresis of this perma
 Similar anthonis in This filmed
 And on the The Castor
 Descripted to this perma

Descional to citation Report of Revision of Contract

+Letters

Michael R. Skilton, Ph0<sup>8</sup>, Julian G. Ayer, MIRS, Ph0<sup>9</sup>, Jason A. Harmer, BSc\*, Karen Webb, MPH, PhD\*, Stephen R. Leeder, MD, PhO<sup>4</sup>, Guy R. Markx, MIRS, PhD<sup>4</sup>, and David 5. Celermajer, MBBS, PhB

\* Author Affiliation

#### ABSTRACT

Article

ORDECTIVES: Inpaired fetal providi is an independent cardiovascular etak factor and it appocated with arterial wall thickening in children. No presentive strategy has been identified. We assight to determine whether detary onega-5 fatty acid applementation during early childhood prevents the association between impaired field growth and carotid arterial wall

Re clarger multiplet METHODS: The Childhood Authors: Prevention Study was a randomized, controlled single-blind trial in EV6 shiften born at term, rescribed Crising initialized anternatally from maternity hospitals in Sydney, Participants were Google lahotar andonized to either a 500-reg-daily fith sil supplement and carela-based Fundied margarites and cooking oil lonega-1 group), or a 500-mg-daily sambower oil supplement and onega-6 fatty acid-tich margarites and cooking oil Social Bookmarking Innega-1 group In = 1871 control group In = 1763.

appediatric UN Promoting Padiatri Coding Excellence Correct, Compliant Pediatric Coding Starts Here.

Har (ta) (16:28m

18

## **NEW GROWTH HORIZONS**



#### • Continued focus on the infant formula and children's food market.

- Specialist delivery systems.
- Targeted multiple bioactive delivery systems.
- Improved bioactive protection.
- Provision of improved value.
- Develop medical food opportunities
  - products for improved cognitive & respiratory development in preterm infants.
  - Product development supported by a major clinical trial underway
- Exploring new ways to commercialize Clover intellectual property including licensing.
  - The outcomes for the innovation program may have applicability beyond Clover's commercial focus.
- Assessing new bioactives.
- Developing new markets/applications.



#### **FY2013 OUTLOOK & PRIORITIES**

- Outlook is promising for FY2013 following the good performance in FY2012.
- Continued organic growth with emphasis on Oceania, Asia and the Americas.
- Initial sales from products provided for customer evaluation in 2011.
- Advance the innovation program for specialty infant formula ingredients and medical food applications.
- Competitive market will continue to see pressure on product margins.
- Continue to improve efficiencies and reduce costs.



## **THANK YOU** Questions?

NEXT GENERATION NUTRITION



#### DISCLAIMER

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law.

Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor. Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Clover Corporation's current expectations, estimates and projections about the industry in which Clover Corporation operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Clover Corporation, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Clover Corporation cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Clover Corporation only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Clover Corporation will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.